Insta
Swarajya Staff
Dec 23, 2016, 08:35 PM | Updated 08:35 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
In a major milestone in the fight against future Ebola outbreak, an experimental vaccine has been found to be highly protective against the deadly virus, as per results of the final trial led by the World Health Organisation (WHO).
The vaccine is the first to prevent infection from one of the most lethal known pathogens, according to the results published in The Lancet journal. Marie-Paule Kieny, WHO's Assistant Director-General for Health Systems and Innovation, and the study's lead author, said:
While these compelling results come too late for those who lost their lives during West Africa’s Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless.
In the most recent Ebola outbreak in West Africa that started in late 2013, more than 11,000 people lost their lives. The WHO removed the global emergency tag for the disease early this year.
The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11,841 people in Guinea during 2015. Among the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine.
The trial was led by the World Health Organization, together with Guinea's Ministry of Health and other international partners.
The vaccine works by replacing a gene from a harmless virus known as vesicular stomatitis virus (VSV) with a gene encoding an Ebola virus surface protein. The vaccine does not contain any live Ebola virus.
Since Ebola virus was first identified in 1976, sporadic outbreaks have been reported in Africa. But the 2013-2016 West African Ebola outbreak, which resulted in more than 11,000 deaths, highlighted the need for a vaccine.
With inputs from IANS